Literature DB >> 22231694

[Albuminuria : prognostic marker or therapeutic goal?].

C Chatzikyrkou1, H Haller, J Menne.   

Abstract

Microalbuminuria has most often been linked with renal disease in diabetic patients. However, accumulating data demonstrate that the development of albuminuria is closely associated with cardiovascular and renal disease in both diabetic and non-diabetic patients. The role of albuminuria in the pathogenesis of these clinical conditions remains controversial. While reductions in albuminuria have been associated with improved outcomes, the evidence for lower levels of albuminuria (microalbuminuria and normoalbuminuria) is inconclusive. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have demonstrated some success in treating or delaying the onset of microalbuminuria. However, it remains to be established whether these effects result in meaningful reductions in clinical renal or cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231694     DOI: 10.1007/s00108-011-2891-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  36 in total

1.  Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts.

Authors:  Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

2.  Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study.

Authors:  Marcello Tonelli; Paul Muntner; Anita Lloyd; Braden J Manns; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Brenda R Hemmelgarn
Journal:  Ann Intern Med       Date:  2011-01-04       Impact factor: 25.391

3.  Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity.

Authors:  H L Hillege; W M Janssen; A A Bak; G F Diercks; D E Grobbee; H J Crijns; W H Van Gilst; D De Zeeuw; P E De Jong
Journal:  J Intern Med       Date:  2001-06       Impact factor: 8.989

4.  Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.

Authors:  Folkert W Asselbergs; Gilles F H Diercks; Hans L Hillege; Ad J van Boven; Wilbert M T Janssen; Adriaan A Voors; Dick de Zeeuw; Paul E de Jong; Dirk J van Veldhuisen; Wiek H van Gilst
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

5.  Relation between kidney function, proteinuria, and adverse outcomes.

Authors:  Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli
Journal:  JAMA       Date:  2010-02-03       Impact factor: 56.272

6.  Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective.

Authors:  H-H Parving; J B Lewis; M Ravid; G Remuzzi; L G Hunsicker
Journal:  Kidney Int       Date:  2006-06       Impact factor: 10.612

7.  Predicting diabetic nephropathy in insulin-dependent patients.

Authors:  C E Mogensen; C K Christensen
Journal:  N Engl J Med       Date:  1984-07-12       Impact factor: 91.245

8.  Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality.

Authors:  Hiddo J Lambers Heerspink; Auke H Brantsma; Dick de Zeeuw; Stephan J L Bakker; Paul E de Jong; Ron T Gansevoort
Journal:  Am J Epidemiol       Date:  2008-09-05       Impact factor: 4.897

9.  Albuminuria, but not estimated glomerular filtration rate, is associated with maladaptive arterial remodeling: the Hoorn Study.

Authors:  Marc M H Hermans; Ronald M A Henry; Jaqueline M Dekker; Giel Nijpels; Rob J Heine; Coen D A Stehouwer
Journal:  J Hypertens       Date:  2008-04       Impact factor: 4.844

10.  Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.

Authors:  Simon J Griffin; Knut Borch-Johnsen; Melanie J Davies; Kamlesh Khunti; Guy E H M Rutten; Annelli Sandbæk; Stephen J Sharp; Rebecca K Simmons; Maureen van den Donk; Nicholas J Wareham; Torsten Lauritzen
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.